Kornimate/medical-research-clean huggingface dataset:
testing the neuroscience of guided learning in depression

Conditions: Major Depressive Disorder

Summary: major depression is a prevalent and impairing illness. to better understand the basic science and treatment of depression, the investigators study the behavioral and brain processes associated with learning in depression and how potential disruptions in learning may be repaired. understanding different methods that change learning may lead to novel treatments that contribute to recovery in people with depression.

major depressive disorder ranks among the most significant causes of mortality and disability in the world. recent data from the investigators and others highlight that impairments in reward and loss learning are central to depression, have distinct neural substrates, and improve with successful treatment. together, these findings suggest an urgent need to delineate the relationships among neural and behavioral learning impairments and depression. equally important, these insights suggest new targets for treatment such that manipulating the neural and behavioral substrates of learning may facilitate symptom change in depression. to address these issues, the investigators use functional neuroimaging and a computational psychiatry framework to i) systematically characterize the neural and behavioral substrates that attend reward- and loss- learning in depression and ii) assess the degree to which learning in depression responds to two behavioral methods that target learning in different ways. the investigators test the broad hypotheses that i) that depression may be characterized by distinct neural and behavioral disruptions of learning, and ii) these disruptions and associated symptoms may be ameliorated through different methods of guiding learning. recent advances in computational psychiatry provide a mechanism-based framework within which to understand the nature and trajectory of potential learning impairments in depression and suggest new ways that disrupted learning and associated symptoms may be improved in depression

Eligibility criteria:
inclusion criteria: * males and females of all ethnicities * meet diagnostic criteria for major depression or non-depressed control (assessed by study staff) * ages 18-55 * fluent in english * able to see computer display clearly * able to provide informed consent * able to follow verbal or written instructions * for participants who are referred by a clinician, a letter from that clinician indicating that participation in the study does not constitute an elevated medical or behavioral risk to the participant will be requested. exclusion criteria: * current pregnancy or menopause * claustrophobia * mri contraindications * psychotic or bipolar disorder
controlled study of the use of quetiapine fumarate in the treatment of patients with bipolar depression

Conditions: Bipolar Disorder

Summary: the purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.


Eligibility criteria:
inclusion criteria: * provision of informed consent before enrollment and any study-specific procedures. patients deemed incapable of providing written consent will not be enrolled in this study; outpatient status exclusion criteria: * more than 8 mood episodes in the past year from screen (visit 1); * a current axis i disorder other than bipolar disorder within 6 months of screening; * patients with clinically significant abnormal laboratory findings in the investigator's judgment

Keywords: bipolar i disorder
neurological monitoring in patients switching from dolutegravir based regimen to bictegravir based regimen

Conditions: HIV-1-infection

Summary: prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. the hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir.

prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. the hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir. the main outcome measure will be a global severity index (gsi) of neuropsychiatric symptoms arising from 10 symptom domains, including somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism. the secondary outcomes are to compare, between arms and during follow up, neuropsychiatric symptoms severity, neurocognitive performance, changes in self-reported symptoms, adherence and hr-qol, correlation between symptoms (neuropsychiatric and other), drug exposure and hr-qol, proportion of adverse events, proportion of virological failures and antiretrovirals resistance at virological failure.

Eligibility criteria:
inclusion criteria: * age \>18 years * hiv-1 infection * hiv rna \ 12 months (including patients with 1 blip 50-200 cp/ml before screening, not confirmed) * on treatment with dolutegravir/abacavir/lamivudine \>6 months exclusion criteria: * previous aids events * pregnancy or pregnancy plan * decompensated cirrhosis (b or c cpt status) * intake of alcohol, substances, other drugs that may affect neurocognitive performances * necessity to receive drugs that may require dosing adjustment of dolutegravir or bictegravir * certified diagnosis of major depression, psychosis, history of suicidal attempts * treatment with antidepressants or antipsychotic drugs * history of virological failure with instis * lack of knowledge of italian language * impossibility to obtain informed written consent * hbsag positivity * estimated glomerular filtration rate by ck-epi \<50 ml/min per 1.73 m2

Keywords: hiv neurocognitive functions neuropsychiatric side effects bictegravir insti
circadian rhythms and sleep in familial dsps and asps

Conditions: Circadian Rhythm Sleep Disorder

Summary: the purpose of this study is to determine the properties of circadian rhythms and sleep propensity in familial advanced and delayed sleep phase syndrome (dsps).

background: tremendous progress in the past few years has led to the identification of several circadian clock genes. this now makes it possible to determine how alterations of human circadian clock genes and their expression could lead to differences in circadian and sleep/wake cycle phenotypes. of particular interest for understanding genetics of the human circadian system are individuals with sleep phase disorders, such as dsps and advanced sleep phase syndrome (asps), because recent studies indicate a genetic basis for these disorders. while it is assumed that both asps and dsps are disorders of circadian timing, little is known about how the circadian clock system, or its interaction with sleep processes, are affected in these individuals. design narrative: participants will complete questionnaires and actigraphy to determine sleep patterns and quality.

Eligibility criteria:
inclusion criteria for asps participants: * morning type score on the horne-ostberg questionnaire * advanced melatonin onset inclusion criteria for dsps participants: * evening type score on the horne-ostberg questionnaire * delayed melatonin onset inclusion criteria for controls: * a stable sleep/wake pattern with a normal phase relationship to the environment and no history of sleep disorders exclusion criteria for all subjects: * sleep disorder, other than dsps or asps, as assessed by the pittsburgh sleep quality index and/or by polysomnogram * history of cognitive or other neurological disorders * history of diagnostic and statistical manual-iv criteria for any major psychiatric disorder, alcohol or substance abuse * abnormal mood as assessed by the hamilton depression scale * history of, or concurrent, unstable or serious medical illness * current use of psychoactive medications, including antidepressants, anxiolytics, neuroleptics, anticonvulsants, hypnotics, and stimulant medications * shift work * having a daily caffeine intake greater than 4 cups per day * smoking * travel across more than 2 time zones within 90 days of the study * pregnancy or the desire to become pregnant during the study period

Keywords: circadian advanced sleep phase delayed sleep phase
a study to test long-term treatment with spesolimab in patients with fistulising crohn's disease who took part in previous trials

Conditions: Crohn Disease

Summary: the main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of spesolimab in patients with perianal fistulising crohn's disease, who have completed treatment in parent trials


Eligibility criteria:
inclusion criteria: 1. patient older than 18 years 2. has completed all treatments (placebo or active treatment) and the end of treatment (eot) visit in the parent induction trial in fistulising crohn's disease (cd) and is willing and able to continue treatment in 1368-0007 3. has obtained an individual health benefit, per investigator judgement (such as fistula response or remission or other clinical improvement), from treatment in the parent trial 4. signed and dated written informed consent for 1368-0007 in accordance with gcp and local legislation prior to admission into the trial 5. women of childbearing potential (wocbp) must be ready to use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly. a list of contraception methods meeting these criteria is provided in the patient information exclusion criteria: 1. have experienced treatment-limiting adverse events during induction treatment with study drug 2. have developed any condition which meets the exclusion criteria from the original induction study 3. any condition which in the opinion of the investigator affects the safety or ability to participate in this trial
risperidone (risperdal) augmentation in depressed partial responders to sri treatment

Conditions: Treatment Resistant Depression

Summary: this is a study of the chemistry of depression in people who are taking an antidepressant but it is not working well. the changes in brain chemicals that occur when an ssri type antidepressant is supplemented with risperidone (risperdal®) will be studied. spinal fluid is used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression. the study has potential to help understand and treat depression.


Eligibility criteria:
inclusion criteria: * treatment-resistant unipolar depression (previous diagnosis of mdd by scid-p or dsm-iv) as defined by inadequate or waning response to adequate sri treatment for at least 4 weeks * hrsd (17-item) score greater than or equal to 15 while taking an sri with no past suicide attempts for one year and no current ideation, intent, or plan. repeat hrsd scores should remain greater than or equal to 15 for two consecutive weeks after initial screening. exclusion criteria: * adverse extrapyramidal or other response to dopamine antagonist effects in the past. * any adverse response to risperidone in the past. * residence beyond 30 miles from vanderbilt university. * inability to comply with study requirements. * psychotic hallucinations * past diagnosis of bipolar, dissociative, or psychotic disorders. * substance or alcohol abuse, other psychotropic, or any investigational or herbal preparation within 3 months or substance dependency within 6 months prior to initial screening (by scid-p). * history of impulsive suicidal gestures or attempts within 2 years (must have no suicidal ideation, intent or plan for a period of one year). * primary diagnosis of cluster b or c personality disorder, or significant comorbidity due to borderline, antisocial, schizoid, or schizotypal personality disorder (by scid-ii). * seasonal affective syndromes, including seasonal affective disorder (because the duration of the study is long enough to expect "spontaneous" \[natural\] remissions.) * chronic (daily) benzodiazepine use in the past month or any use 1 week prior to sampling. * regular analgesic use. no antipyretic medication is allowed in the pre- through post-sampling period, leaving difficulty with pain management for pain-prone patients. * medication use deemed by the investigator unacceptable for study protocol. * pregnancy or inability to cooperate with effective contraceptive method (double barrier). * physical condition or significant medical history of any illness that presents risk with lumbar catheterization. * lactation. * blood donation within 90 days prior to or planned 90 days following the study. * severe migraine history. * daily tobacco use (absolute abstinence is required during the entire study.)
using eeg operant conditioning to improve trait self-control and promote healthy behavior

Conditions: Obesity; Type II Diabetes; Cardiovascular Disease; Health Behavior

Summary: the field of neuroeconomics has begun to elucidate neural mechanisms underlying self-control; however, researchers have not yet harnessed neuroeconomics findings to develop interventions for improving self-control ability. the investigators are currently developing such an intervention. the investigators' approach involves using a brain-computer interface with audiovisual feedback to show people what is happening in their own brains, in real time. through this interface, individuals are trained to increase levels of neural activity that may facilitate self-control, which, in turn, may improve the ability to exhibit self-controlled behaviors. this may increase the ability to engage in heath behaviors for which self-control is required (eg, dieting and exercising). the investigators' long-term goal is to create a tool that will help people develop the self-control needed to achieve lasting improvements in health behaviors.


Eligibility criteria:
inclusion criteria: * can read and write fluently in english * at least 18 years of age * right-handed * overweight or obese (bmi \> 24.9) * currently has a university of rochester meal plan * currently in contemplation or action stages of change with respect to weight loss (measured with the weight stages of change algorithm; rossi, rossi, velicer, \& prochaska, 1995). exclusion criteria: * history of diabetes, epilepsy, celiac disease, lactose intolerance, food allergies, veganism, mental illness, or eating disorders * currently taking a medication that may have a strong effect on eeg recordings (eg, an antidepressant, stimulant medication, etc.) * currently drinks more than 3 cups of coffee per day or roughly equivalent caffeine intake

Keywords: obesity type ii diabetes cardiovascular disease health behavior promotion neuroeconomics eeg biofeedback low-resolution electromagnetic tomography (loreta) eeg
antimicrobials stewardship by pharmacist

Conditions: Infection

Summary: to study the outcome of antibiotics stewardship

retrospective cohort study by medical review and evaluation of broad-spectrum antibiotics to determine how appropriately it was bing used.

Eligibility criteria:
inclusion criteria: * inpatient with infectious disease and under broad-spectrum antibiotics exclusion criteria: * poor prognosis was diagnosed or received conservative therapy only.

Keywords: broad-spectrum antimicrobial antibiotics pharmacist
adalimumab in adult japanese subjects with moderate to severe chronic plaque psoriasis

Conditions: Psoriasis

Summary: the purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult japanese subjects with moderate to severe chronic plaque psoriasis.


Eligibility criteria:
inclusion criteria: * subject was age 20 or older and in good health (investigator discretion) with a recent stable medical history. * subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis exclusion criteria: * subject had previously received anti-tnf therapy. * subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid uva, uvb or puva phototherapy * subject is taking or requires oral or injectable corticosteroids * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study * female subject who is pregnant or breast-feeding or considering becoming pregnant
study of acthar® gel (acthar) for amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: about 213 people with als will participate in this study. there will be locations in north and south america. during the first part, participants will be randomly assigned to a group (like by flipping a coin). out of every 3: * 2 will get the study drug * 1 will get a look-alike with no drug in it (placebo) during the second part, everyone will get the study drug. participation will help doctors find out if acthar can help or slow down the symptoms of als better than placebo.

this is a multicenter, multiple dose study to examine the effect of acthar on functional decline in adult participants with als. approximately 213 participants will be enrolled. following a screening period of up to 28 days, participants with als and symptom onset (defined as first muscle weakness or dysarthria) ≤ 2 years prior to the screening visit will be randomized on a 2:1 basis to receive subcutaneous (sc) acthar 0.2 ml (16 units \[u\]) daily (qd) or sc matching placebo 0.2 ml qd for 36 weeks, followed by a 3-week taper. participants who complete the 36 week double-blind treatment period are eligible to enter an open label extension phase in which all participants will receive acthar 0.2 ml (16 u) daily.

Eligibility criteria:
inclusion criteria: 1. is 18-75 years of age at screening 2. has als symptom onset within 2 years prior to screening 3. has forced vital capacity (fvc) no higher than 60% at screening 4. if taking riluzole, is on a stable dose for 4 weeks before screening exclusion criteria: 1. has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any type 2. has used any medication within a time period not allowed per protocol 3. has history of type 1 or type 2 diabetes mellitus, or any clinically significant infection 4. used edaravone less than 1 week before screening 5. received any stem cell replacement therapy 6. used steroids within a time period not allowed per protocol

Keywords: als
the effectiveness of msat for patients with rom limitation of the shoulders

Conditions: Shoulder Joint Disorder

Summary: this study is a prospective, case-control observational trial. the investigators will compare the msat group to the control group to analyze the effectiveness of shoulder msat.

motion style acupuncture treatment(msat) is a therapeutic technique using acupuncture needle created in jaseng hospital. this treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation. this treatment is known to relieve the pain and increase the range of motion(rom). however, there has been no specific value for the effect of this treatment. therefore, the investigators conducted observational trial to analyze the effectiveness of shoulder msat. from july 2019, the investigators will collect 80 patients with rom limitation on both or each shoulder and who are suffering from shoulder pain with the numeric rating scale(nrs) over 4. the investigators will compare pain, dysfunction, quality of life and satisfaction of patients who are treated with korean medical treatment including msat and patients who are treated with korean medical treatment not including msat. for these two groups, the investigators will compare range of motion(rom), nrs(numeric rating scale), visual analogue scale(vas), shoulder pain and disability index(spadi), patient global impression of change (pgic) and euroqol 5-dimension (eq-5d-5l).

Eligibility criteria:
inclusion criteria: * patients with more than one rom limitation(abduction 180˚, adduction 45˚, flexion 180˚, extension 45˚, int. rot 80˚, ext. rot 80˚) on both or each shoulder. * patients with nrs ≥ 4 for shoulder pain * patients aged 19-70 years on the date they sign the consent form. * patients who provide consent to participate in the trial and return the informed consent form exclusion criteria: * patients who have been diagnosed with a severe disease that may cause rom limitation of shoulder or shoulder pain, * patients with progressive neurological deficit or with serious neurological symptoms caused by spinal cord compression. * patients who visited a hospital in pain caused by a traffic accident. * patients with a severe mental illness. * patients who are difficult to complete the research participation agreement

Keywords: shoulder joints rom shoulder disorder msat motion style acupuncture treatment shoulder pains
virtual reality in reeducation : application to shoulder affections

Conditions: Scapular Dyskinesis; Shoulder Pain

Summary: the objective of this study is to assess the interest and the efficiency of virtual reality in functional rehabilitation of shoulder pain and shoulder injuries. participants will follow a 12-week rehabilitation program based either on exercises or on a program integrating virtual reality. results obtained with classical rehabilitation will be compared with the one obtained virtual reality.

fifty people will be included in the study. then, they were randomly separated in two groups : 25 people will do the "classical rehabilitation" and the other 25 will have a treatment with virtual reality. each group (virtual reality and "classical rehabilitation") is going to follow 12 weeks of rehabilitation, at a rate of 2x 30 minutes per week. in "virtual reality group", each session will be divided in two parts : 15 minutes of virtual reality exercises and 15 minutes of exercises from "classical program". exercises suggested in the classical program have been chosen among evidence based exercises described in literature. before the beginning of rehabilitation sessions, participants will be assessed at the laboratory of human motion analysis of the university of liege. at this place, emg activity of periscapular muscles (upper trapezius, lower trapezius and serratus anterior) (delsys trigno) , 3d scapular kinematics (codamotion) will be assessed on the painful side when doing shoulder elevations in sagittal and in frontal planes. maximum isometric strength will also be assessed using handheld dynamometer (microfet2) in 3 different positions (seatedu90°, seatedu125°, prone-v-thumbs up) this first evaluation will be done after the 12 week of rehabilitation too, with the same method. participants will also have to complete dash (disability of the arm, shoulder and hand) questionnaire 3 times during the study (at the beginning, at 6 weeks and at the end of the study). moreover, pain score will be asked to participants at each rehabilitation session.

Eligibility criteria:
inclusion criteria: * unilateral scapular dyskinesis * positive scapular assistance test and positive resistance test * shoulder pain * ability to play sport despite shoulder pain * one or more positive tendinous tests exclusion criteria : * traumatic history of shoulder injury in the last 6 months * surgical history at shoulder or cervical location * scoliosis